Yüklüyor......
APPRISE Oncology Program for Erythropoiesis-Stimulating Agents
The FDA recently announced an oncology-specific Risk Evaluation and Mitigation Strategy for erythropoiesis-stimulating agents prescribed under approved indications: The APPRISE program.
Kaydedildi:
| Yazar: | |
|---|---|
| Materyal Türü: | Artigo |
| Dil: | Inglês |
| Baskı/Yayın Bilgisi: |
American Society of Clinical Oncology
2010
|
| Konular: | |
| Online Erişim: | https://ncbi.nlm.nih.gov/pmc/articles/PMC2868643/ https://ncbi.nlm.nih.gov/pubmed/29436948 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1200/JOP.092002 |
| Etiketler: |
Etiketle
Etiket eklenmemiş, İlk siz ekleyin!
|